{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:24Z","timestamp":1787020824531,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nordic Bioscience A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Associations between rheumatoid arthritis (RA) and effect of treatment at the tissue levels are poorly understood. We investigated the scope of released extracellular matrix (ECM) metabolites as a consequence of tissue remodelling in patients treated with methotrexate (MTX) and tocilizumab (TCZ) compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tissue metabolites from 387 RA patients treated with either TCZ (8\u2009mg\/kg) or MTX monotherapy (7.5\u201320\u2009mg\/kg) were measured at baseline and 8\u2009weeks sera by validated ELISA assays. The levels of collagen biomarkers (C1M, C2M, C3M and C4M) together with C-reactive protein (CRP) and CRP metabolite (CRPM) were investigated. Baseline levels of biomarkers have been compared with 72 age- and gender-matched healthy controls. Comparison between treatment and response groups were done by ANCOVA, Spearman\u2019s correlation and logistic regression adjusted for age, gender, BMI and disease duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      C1M and C3M were significantly (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) inhibited by TCZ and C3M by MTX (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) compared to placebo. C1M and C3M inhibition with TCZ was respectively 23% and 16% greater than that of MTX (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). C4M was inhibited by TCZ and MTX, but the effect of TCZ was 22% greater than MTX (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). TCZ and MTX had minimal effect on C2M levels. MTX had no effect on CRP and CRPM, whereas TCZ reduced their levels to 69% and 27% from baseline. Investigated biomarkers revealed a significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) difference in biomarker profiles of MTX ACR50 treatment responders and non-responders. Change to week 8 in levels of C3M, C4M, CRP and CRPM in MTX patients correlated significantly (rho\u2009=\u20090.41 to 0.18,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 to 0.039) with change in disease activity (DAS28) at weeks 8, 16 and 24, whereas only CRP in TCZ patients (rho\u2009=\u20090.32 to 0.21,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 to 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients receiving TCZ treatment for 8\u2009weeks had higher suppression of tissue remodelling and inflammatory biomarkers over patients treated with MTX. Measured biomarkers enabled for a discrimination of biomarker profiles of ACR50 treatment responding patients and identification of those who benefit at the early time point. Week 8 change in levels of C3M, C4M, CRP and CRPM significantly predicted clinical response to treatment and correlated with DAS28 at all time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00109408\">NCT00109408<\/jats:ext-link>\n                      . Date of registration: July 2005. Name of the registry: A Study to Assess the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02378-7","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T07:03:47Z","timestamp":1610003027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study"],"prefix":"10.1186","volume":"23","author":[{"given":"Patryk J.","family":"Drobinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Sardar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Siebuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"3","key":"2378_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0000000000000267","volume":"28","author":"M Dougados","year":"2016","unstructured":"Dougados M. Comorbidities in rheumatoid arthritis. Curr Opin Rheumatol. 2016;28(3):282\u20138 https:\/\/doi.org\/10.1097\/BOR.0000000000000267.","journal-title":"Curr Opin Rheumatol"},{"key":"2378_CR2","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB Mcinnes","year":"2011","unstructured":"Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319 https:\/\/doi.org\/10.1056\/NEJMra1004965.","journal-title":"N Engl J Med"},{"issue":"8","key":"2378_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/ncprheum0249","volume":"2","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nature. 2006;2(8):425\u201333 https:\/\/doi.org\/10.1038\/ncprheum0249.","journal-title":"Nature"},{"key":"2378_CR4","doi-asserted-by":"publisher","unstructured":"Sardar S, Andersson \u00c5. Old and new therapeutics for rheumatoid arthritis: in vivo models and drug development. Immunopharmacol Immunotoxicol. 2016:1\u201312 https:\/\/doi.org\/10.3109\/08923973.2015.1125917.","DOI":"10.3109\/08923973.2015.1125917"},{"key":"2378_CR5","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2146\/ajhp050514","volume":"63","author":"A Gaffo","year":"2006","unstructured":"Gaffo A, Saag K, Curtis J. Treatment of rheumatoid arthritis. Am J Health-Syst Pharm. 2006;63:2451\u201365 https:\/\/doi.org\/10.2146\/ajhp050514.","journal-title":"Am J Health-Syst Pharm"},{"issue":"3","key":"2378_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/erp.12.27","volume":"12","author":"A Reynolds","year":"2012","unstructured":"Reynolds A, Koening AS, Bananis E, Singh A. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):319\u201333 https:\/\/doi.org\/10.1586\/erp.12.27.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2378_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00832010","volume":"20","author":"K Yoshizaki","year":"1998","unstructured":"Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol. 1998;20:247\u201359 https:\/\/doi.org\/10.1007\/bf00832010.","journal-title":"Springer Semin Immunopathol"},{"issue":"2","key":"2378_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal MA, Schett G, Emery P, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the Tocilizumab RADIATE study. Semin Arthritis Rheum. 2012;42(2):131\u20139 https:\/\/doi.org\/10.1016\/j.semarthrit.2012.01.004.","journal-title":"Semin Arthritis Rheum"},{"key":"2378_CR9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2018-214894","volume":"6","author":"S Finzel","year":"2019","unstructured":"Finzel S, Kraus S, Figueiredo CP, et al. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019;6:1186\u201391 https:\/\/doi.org\/10.1136\/annrheumdis-2018-214894.","journal-title":"Ann Rheum Dis"},{"key":"2378_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00307733","volume":"13","author":"U Sack","year":"1993","unstructured":"Sack U, Kinne R, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13:45\u201351 https:\/\/doi.org\/10.1007\/BF00307733.","journal-title":"Rheumatol Int"},{"key":"2378_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/ard.52.3.232","volume":"52","author":"R Madhok","year":"1993","unstructured":"Madhok R, Crilly A, Watson J, Capell HA, Royal G. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232\u20134 https:\/\/doi.org\/10.1136\/ard.52.3.232.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2378_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609\u201321 https:\/\/doi.org\/10.1002\/art.30158.","journal-title":"Arthritis Rheum"},{"key":"2378_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB Mcinnes","year":"2007","unstructured":"Mcinnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthrits. Nat Rev Immunol. 2007;7:429\u201342 https:\/\/doi.org\/10.1038\/nri2094.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2378_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/adt.2012.474","volume":"11","author":"MA Karsdal","year":"2013","unstructured":"Karsdal MA, Nielsen MJ, Sand JM, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Assay Drug Dev Technol. 2013;11(2):70\u201392 https:\/\/doi.org\/10.1089\/adt.2012.474.","journal-title":"Assay Drug Dev Technol"},{"key":"2378_CR15","doi-asserted-by":"publisher","unstructured":"Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3 https:\/\/doi.org\/10.1101\/cshperspect.a005058.","DOI":"10.1101\/cshperspect.a005058"},{"key":"2378_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.62.suppl_2.ii43","volume":"62","author":"FF Mohammed","year":"2003","unstructured":"Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis. 2003;62:43\u20137 https:\/\/doi.org\/10.1136\/ard.62.suppl_2.ii43.","journal-title":"Ann Rheum Dis"},{"key":"2378_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2741\/1817","volume":"11","author":"PS Burrage","year":"2006","unstructured":"Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529\u201343 https:\/\/doi.org\/10.2741\/1817.","journal-title":"Front Biosci"},{"key":"2378_CR18","first-page":"94","volume":"36","author":"AS Siebuhr","year":"2018","unstructured":"Siebuhr AS, Sun S, Byrjalsen I. Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis. Clin Exp Rheumatol. 2018;36:94\u2013101 https:\/\/www.clinexprheumatol.org\/abstract.asp?a=11449.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2378_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13547500902777608","volume":"14","author":"MA Karsdal","year":"2009","unstructured":"Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14(3):181\u2013202 https:\/\/doi.org\/10.1080\/13547500902777608.","journal-title":"Biomarkers"},{"issue":"4","key":"2378_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","volume":"43","author":"AC Bay-Jensen","year":"2014","unstructured":"Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum. 2014;43(4):470\u20138 https:\/\/doi.org\/10.1016\/j.semarthrit.2013.07.008.","journal-title":"Semin Arthritis Rheum"},{"key":"2378_CR21","doi-asserted-by":"publisher","unstructured":"Bay-Jensen AC, Platt A, Siebuhr AS, Christiansen C, Byrjalsen I, Karsdal MA. Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Res Ther. 2016:7\u201315 https:\/\/doi.org\/10.1186\/s13075-015-0913-x.","DOI":"10.1186\/s13075-015-0913-x"},{"key":"2378_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4266","volume":"15","author":"AS Siebuhr","year":"2013","unstructured":"Siebuhr AS, Bay-Jeensen AC, Leeming DJ, et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther. 2013;15:1\u20139 https:\/\/doi.org\/10.1186\/ar4266.","journal-title":"Arthritis Res Ther"},{"key":"2378_CR23","first-page":"829","volume":"36","author":"NS Gudmann","year":"2018","unstructured":"Gudmann NS, Junker P, Juhl P, et al. Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis. Clin Exp Rheumatol. 2018;36:829\u201335 https:\/\/www.clinexprheumatol.org\/article.asp?a=12293.","journal-title":"Clin Exp Rheumatol"},{"key":"2378_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3109\/s10165-012-0782-y","volume":"23","author":"T Kojima","year":"2013","unstructured":"Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol. 2013;23:977\u201385 https:\/\/doi.org\/10.1007\/s10165-012-0782-y.","journal-title":"Mod Rheumatol"},{"key":"2378_CR25","first-page":"568","volume":"36","author":"P Juhl","year":"2018","unstructured":"Juhl P, Thudium CS, Gudmann NS, Karsdal MA, Siebuhr AS. IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study. Clin Exp Rheumatol. 2018;36:568\u201374 https:\/\/www.clinexprheumatol.org\/article.asp?a=12085.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2378_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/RHU.0000000000000150","volume":"20","author":"A Bay-jensen","year":"2014","unstructured":"Bay-jensen A, Byrjalsen I, Siebuhr AS, et al. Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline. J Clin Rheumatol. 2014;20(6):332\u20135 https:\/\/doi.org\/10.1097\/RHU.0000000000000150.","journal-title":"J Clin Rheumatol"},{"key":"2378_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88\u201396 https:\/\/doi.org\/10.1136\/ard.2008.105197.","journal-title":"Ann Rheum Dis"},{"key":"2378_CR28","doi-asserted-by":"publisher","unstructured":"Leeming DJ, He Y, Veidal SS, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16(7) https:\/\/doi.org\/10.3109\/1354750X.2011.620628.","DOI":"10.3109\/1354750X.2011.620628"},{"key":"2378_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clinbiochem.2011.01.001","volume":"44","author":"AC Bay-Jensen","year":"2011","unstructured":"Bay-Jensen AC, Liu Q, Byrjalsen I, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM \u2014 increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem. 2011;44:423\u20139 https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.01.001.","journal-title":"Clin Biochem"},{"key":"2378_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","volume":"43","author":"N Barascuk","year":"2010","unstructured":"Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43:899\u2013904 https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.03.012.","journal-title":"Clin Biochem"},{"key":"2378_CR31","doi-asserted-by":"publisher","unstructured":"Karsdal MA, Genovese F, Madsen EA, Manon-Jensen T, Schuppan D. Collagen and tissue turnover as function of age: implications for fibrosis. J Hepatol. 2015;64(1) https:\/\/doi.org\/10.1016\/j.jhep.2015.08.014.","DOI":"10.1016\/j.jhep.2015.08.014"},{"issue":"1","key":"2378_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0054504","volume":"8","author":"AC Bay-Jensen","year":"2013","unstructured":"Bay-Jensen AC, Wichuk S, Byrjalsen I, et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One. 2013;8(1):1\u20137 https:\/\/doi.org\/10.1371\/journal.pone.0054504.","journal-title":"PLoS One"},{"issue":"2","key":"2378_CR33","first-page":"166","volume":"66","author":"T Sokka","year":"2008","unstructured":"Sokka T. Radiographic scoring in rheumatoid arthritis: a short introduction to the methods. Bull NYU Hosp Jt Dis. 2008;66(2):166\u20138 https:\/\/pubmed.ncbi.nlm.nih.gov\/18537790\/.","journal-title":"Bull NYU Hosp Jt Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02378-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-02378-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02378-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T10:19:23Z","timestamp":1610273963000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02378-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02378-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38371\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38371\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The AMBITION study (NCT00109408) was approved by the ethics committee at each participating institution (in USA, Canada and Israel) and was conducted in accordance with the principles of good clinical practice and according to the Declaration of Helsinki. All patients included provided written, informed consent before inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anne C. Bay-Jensen (ACBJ), Morten Karsdal (MK), Anne Siebuhr (ASO) and Samra Sardar (SSA) are full-time employees and\/or shareholders at Nordic Bioscience. Patryk Drobinski (PAD) is a full-time employee at University of Copenhagen. PAD has no disclosures and no competing interests. None of the authors received any kind of financial benefits or other bonuses for the work described in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}